Five percent overall, with the composition turning over underneath — what only a product table shows
Pfizer results for the quarter ended March 29, 2026. Total revenues were \$14,451 million, up 5 percent, but by product the two COVID-19 medicines fell around 60 percent while other leading products grew at double-digit rates.
Filing key facts
- CompanyPFIZER INC (PFE)
- FormCurrent report (8-K)
- ExchangeNYSE
- Industry (SIC)Pharmaceutical Preparations
- Filing date2026-05-05
- Period2026-05-05
- 8-K events2.02 Results of operations and financial condition, 9.01 Financial statements and exhibits
- Accession no.0000078003-26-000053
Key points
- Pfizer results for the quarter ended March 29, 2026, with total revenues of \$14,451 million, up 5 percent year over year.
- Operationally, excluding currency, growth was 2 percent, and international revenues rose 7 percent as reported but fell 1 percent operationally.
- Comirnaty was \$232 million, down 59 percent, and Paxlovid \$186 million, down 62 percent.
- Eliquis rose 13 percent, Nurtec ODT/Vydura 42 percent and Abrysvo 37 percent.
- The 5 percent overall figure reflects a turnover in which products carry revenue, not gentle growth.
1What the total conceals
Total revenues were $14,451 million, up 5 percent. On that figure alone the quarter reads as modest growth. The product-level breakdown tells a different story.
| Product | Revenue this quarter | Change year over year |
|---|---|---|
| Eliquis | $2,166 million | Up 13 percent |
| Prevnar family | $1,690 million | Up 2 percent |
| Nurtec ODT/Vydura | $353 million | Up 42 percent |
| Abrysvo | $180 million | Up 37 percent |
| Comirnaty | $232 million | Down 59 percent |
| Paxlovid | $186 million | Down 62 percent |
The two COVID-19 medicines fell around 60 percent while other products grew at double-digit rates, the gains filling in for the losses to leave 5 percent overall. What happened in the quarter was not gentle growth but a turnover in which products carry the revenue.
2Operational growth
The release states operational growth alongside reported growth, excluding the effect of currency. Reported revenue rose 5 percent while operationally it rose 2 percent. Internationally the divergence is wider still: up 7 percent as reported, down 1 percent operationally. For companies earning abroad, currency lifts or depresses the figures, so both are customarily presented together.
3What a product table is for
In pharmaceuticals, revenue by product moves sharply with patent terms and the course of infectious disease. A single total cannot show which products carry the business and which are shrinking. A results release under Item 2.02 is an unaudited preliminary account, but its value lies in breakdowns at this grain.
This site also holds records of recalls involving the same company medicines, so products can be followed individually.
Why it matters
Reading only the overall growth rate turns a quarter of composition change into apparent gentle growth. The product breakdown and the currency-adjusted measure have to be read together.
FAQ
Why report growth excluding currency?
Why does the product breakdown matter?
Sources (primary)
This article is an independent organization based on the U.S. SEC official disclosures below. Always verify the exact, latest details with the original filing.
- SEC EDGAR (filing index)
- Primary document (original)
- Accession no.：0000078003-26-000053